Every 10-Q that Colgate-Palmolive Company (CL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CL filings page.
Colgate-Palmolive Company reported higher Q2 2026 sales but lower GAAP earnings as major productivity-program charges weighed on results. Net sales rose 4.9% to $5,361 million, with organic sales up 2.4% on 0.9% volume growth, 1.6% pricing and 2.4% favorable foreign exchange.
Gross profit margin improved to 61.5% from 60.1%, helped by funding-the-growth cost savings and pricing, partly offset by higher raw and packaging costs. GAAP operating profit declined to $1,016 million and diluted EPS to $0.86, driven by $129 million of pre-tax charges from the Strategic Growth and Productivity Program. Excluding these and prior-year acquisition costs, operating profit increased 5% to $1,145 million and diluted EPS 8% to $0.99.
For the first half of 2026, net sales reached $10,686 million while operating cash flow strengthened to $1,742 million. Colgate has incurred $318 million of cumulative pre-tax charges under its productivity program, which is expected to total $350–$550 million and deliver projected annual pre-tax savings of $200–$300 million once fully implemented by 2028.
Colgate-Palmolive Company reported first-quarter 2026 Net sales of $5,324 million, up 8.4% from 2025, driven by 1.1% volume growth, 2.2% higher pricing and 5.1% positive foreign exchange. Organic sales grew 2.9%, with Oral, Personal and Home Care organic sales up 3.1% and Hill’s Pet Nutrition up 2.1%.
Gross profit rose to $3,226 million, though gross margin slipped to 60.6% as significantly higher raw and packaging material costs more than offset funding-the-growth savings and pricing. GAAP operating profit fell to $964 million, but on a non-GAAP basis increased 4% to $1,134 million, reflecting restructuring adjustments.
GAAP diluted EPS declined to $0.80 from $0.85, while non-GAAP diluted EPS increased to $0.97 from $0.91, helped by higher operating profit and share count changes. The Board expanded the Strategic Growth and Productivity Program, raising expected cumulative pre-tax charges to $350–$550 million and targeting annualized pre-tax savings of $200–$300 million by the end of 2028.
Colgate-Palmolive reported Q3 2025 results with net sales of $5,131 and diluted EPS of $0.91. Net income attributable to the company was $735. For the first nine months, net sales were $15,152 and diluted EPS reached $2.67, up from $2.61 a year ago.
The company completed the acquisition of Care TopCo Pty Ltd (Prime100) for AU $471 (approximately $301) on April 30, 2025, expanding Hill’s into fresh pet food in Australia. It also announced a three‑year Strategic Growth and Productivity Program with estimated cumulative pre‑tax charges between $200 and $300, with substantially all charges expected by December 31, 2028.
In the quarter, parties entered into a settlement agreement to resolve an ERISA lawsuit for $332, which received preliminary court approval in October 2025; a final approval hearing is scheduled for January 2026. Nine‑month cash from operations was $2,745; financing included dividends of $1,300 and treasury share purchases of $804. Shares outstanding were 806,064,942 as of September 30, 2025.